Email: cspc@cspc.cn
News
August 23, 2023
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SACUBITRIL VALSARTAN SODIUM TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Next: VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us